The advertisement promotes NUBEQA® (darolutamide), highlighting its new FDA approval for use in metastatic castration-sensitive prostate cancer (mCSPC) in combination with androgen deprivation therapy (ADT), while also providing important safety information regarding ischemic heart disease.
Creative Information
| CID: | ea0bdc6e-08f9-462a-9d43-56daafc28575 |
| CRID: | 82_1075-923953 |
| Domain: | nubeqahcp.com |
| Seat: | PP |
| Size: | 300x250 |
| Bid: | $0.70 |
| Timestamp: | 11/13/2025, 2:52:17 PM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 11/13/2025, 4:12:42 PM | 7.16s | |
| adomain_analysis | success | 11/13/2025, 6:42:09 PM | 5.06s | |
| adomain_capture | success | 11/13/2025, 6:42:03 PM | 0.08s | |
| ad_render | success | 11/13/2025, 4:12:35 PM | 25.41s | |
| brand_mapping | success | 11/13/2025, 2:52:17 PM | 0.11s | |
Analysis Results
Ad Format: banner
Brands: NUBEQA
Sensitive:Pharmaceutical Products
Quality:Adomain not match landing page domain
| Size: | 300x250 | ||||||||||||||||||||||
| Data Transferred: | 1363.31 KB | ||||||||||||||||||||||
| Render Time: | 9.76 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Landing Page: | |||||||||||||||||||||||
| Total Ad Size: | 1363.35 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain
Ad Preview
Landing Page
Creatives
